文献速递肿瘤 PET/CT

[68Ga]Ga-DOTA-FAPI-04 PET/CT 在 [18F]FDG PET/CT 结果不确定患者中的价值

Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-06-25

这项前瞻性研究评估了 [68Ga]Ga-DOTA-FAPI-04 PET/CT 在 [18F]FDG PET/CT 结果不确定患者肿瘤学评估中的潜在价值。共纳入 68 例患者,[68Ga]Ga-DOTA-FAPI-04 PET/CT 在鉴别肿块性病变、寻找不明原发灶、上调肿瘤分期和检测疑似复发方面显示出一定作用,但阅读图像时需注意合并炎症的肿瘤。

要点

  • [68Ga]Ga-DOTA-FAPI-04 PET/CT 在 [18F]FDG PET/CT 结果不确定患者中可能具有互补作用。
  • 该检查鉴别肿块性病变准确率为 12/18(66.7%),检测不明原发灶为 4/6(66.7%)。
  • 上调肿瘤分期 7/21(33.3%),检测疑似复发 20/23(87.0%)。

核心结论

  • 在 [18F]FDG PET/CT 结果不确定的患者中,[68Ga]Ga-DOTA-FAPI-04 可能在鉴别常规影像所见的肿块性病变、定位不明原发灶、修改肿瘤分期和检测疑似复发方面具有互补作用。
  • 阅读 [68Ga]Ga-DOTA-FAPI-04 PET/CT 图像时,对合并炎症的肿瘤需谨慎。

研究设计与样本

  • 前瞻性研究,共纳入 68 例 [18F]FDG PET/CT 结果不确定的患者,进行 [68Ga]Ga-DOTA-FAPI-04 PET/CT 检查。
  • 以组织病理学或随访影像作为最终诊断标准。
  • 肿瘤摄取以最大标准摄取值(SUV)定量。

主要发现

  • 68 例中,18 例(26.5%)用于鉴别常规影像所见的肿块性病变,6 例(8.8%)用于在活检证实的转移性恶性肿瘤中检测不明原发部位,21 例(30.9%)用于肿瘤分期,其余 23 例(33.8%)用于评估疑似疾病复发。
  • 多数原发和转移性病变的 [68Ga]Ga-DOTA-FAPI-04 摄取高于 [18F]FDG,在多种癌症中产生良好的肿瘤-背景对比。
  • [68Ga]Ga-DOTA-FAPI-04 PET/CT 鉴别可疑肿块性病变的准确率为 12/18(66.7%),在 4/6 例不明恶性肿瘤患者中检测到原发部位(66.7%)。
  • 在 7/21 例患者中上调肿瘤分期(33.3%),在 20/23 例患者中检测到疾病复发(87.0%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This prospective study aimed to evaluate the potential usefulness of [68Ga]Ga-DOTA-FAPI-04 positron emission tomography/computed tomography (PET/CT) in the oncological evaluation of patients presenting with inconclusive [18F]FDG PET/CT findings. METHODS: [68Ga]Ga-DOTA-FAPI-04 was performed in patients presenting with inconclusive [18F]FDG PET/CT findings. Tumour uptake was quantified by the maximum standard uptake value (SUV). Histopathology or follow-up imaging served as the standard for the final diagnosis. RESULTS: A total of 68 patients with inconclusive [18F]FDG PET/CT findings underwent additional [68Ga]Ga-DOTA-FAPI-04 PET/CT. Of them, 18 (26.5%) were for discrimination of mass lesions detected on conventional imaging, 6 (8.8%) for detection of the unknown primary site in biopsy-proven metastatic malignancy, 21 (30.9%) for the staging of cancer, and the other 23 (33.8%) for evaluation of suspected disease recurrence. Most of the primary and metastatic lesions demonstrated higher uptake of [68Ga]Ga-DOTA-FAPI-04 than did [18F]FDG, which resulted in favourable tumour-to-background contrast in various types of cancer. As a result, [68Ga]Ga-DOTA-FAPI-04 PET/CT identified suspicious mass lesions with an accuracy of 12/18 (66.7%), detected the primary site in 4/6 patients (66.7%) with unknown malignancy, upgraded tumour staging in 7/21 patients (33.3%), and detected disease recurrence in 20/23 patients (87.0%). CONCLUSIONS: In patients undergoing oncological evaluation with inconclusive [18F]FDG PET/CT findings, [68Ga]Ga-DOTA-FAPI-04 may have a complementary role in discriminating mass lesions on conventional imaging, locating the primary site of unknown malignancy, modifying tumour staging, and detecting suspected disease recurrence. Nevertheless, careful attention should be paid when reading the [68Ga]Ga-DOTA-FAPI-04 PET/CT images in tumours complicated with inflammation.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Chen H, Zhao L, Ruan D, et al. Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings. Eur J Nucl Med Mol Imaging. 2020. PMID: 32588089. doi:10.1007/s00259-020-04940-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。